This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): mesenchymal stem cells (MSC), remestemcel-L, Provacel, MSC-100-IV, TEMCELL HS Inj.
Description: Prochymal is a preparation of adult mesenchymal stem cells (MSC) specially formulated for intravenous infusion. These stem cells are obtained from the bone marrow of volunteer donors between 18-32 years of age. Prochymal is designed to modulate the immune system.
Osiris and Boston Scientific
In March 2003, Osiris entered into a collaboration agreement with Boston Scientific to develop applications of MSC technology to treat acute myocardial infarction and chronic ischemia.
Under the terms of the collaboration, Osiris is responsible for the preclinical development of an MSC biologic drug candidate having application in the covered field, and for associated regulatory filings, and Boston Scientific is responsible for the research and development activities performed following completion of preclinical development of a biologic drug candidate. The collaboration provides for Osiris to manufacture the MSC clinical trial materials, and provides that, upon regulatory approval for commercial sale, Osiris will manufacture and Boston Scientific will have exclusive rights to distribute and sell the product globally. Boston Scientific may also assume the manufacturing rights and responsibilities from Osiris and if it does so the royalty...See full deal structure in Biomedtracker
Partners: JCR Pharmaceuticals Co., Ltd. Osiris Therapeutics, Inc.
Additional information available to subscribers only: